Save to Existing Project
Save to a New Project
Yeda R&D Co. Ltd
Abstract ID: 1552
With the increased use of antibiotics to treat bacterial infections, pathogenic strains have acquired antibiotic resistance. The decrease in antibiotics\' effectiveness has led to a growing need for...
With the increased use of antibiotics to treat bacterial infections, pathogenic strains have acquired antibiotic resistance. The decrease in antibiotics' effectiveness has led to a growing need for novel or improved antibacterial agents. However, single agents directed at an individual target frequently show limited efficacies and poor safety and resistance profiles. Combination therapy with single-target inhibitors is standard therapy against several conditions such as HIV and Helicobacter pylori.
The outlined technology employs a structural analysis approach to develop a novel two-component antibiotic with synergistic activity.
Prof. Ada Yonath, 2009 Nobel Laureate in Chemistry, and colleagues from Weizmann Institute of Science have discovered the sites of binding and the modes of action of two antibacterial agents, lankamycin (LM) and lankacidin, (LC) by crystallographic and biochemical analyses. These two compounds, produced by Streptomyces rochei, bind at neighbouring sites in the large ribosomal subunit, and inhibit successive steps in protein synthesis: formation of the nascent protein chain and its export from the ribosome. Such simultaneous inhibition of bacterial growth results in a synergistic action of these two drugs. Based on these structural studies means for enhancing the synergetic inhibitory effect of LC and LM are also provided. This novel technology demonstrates the utility of structural analysis for providing new directions for drug discovery.
Our research proposes synergistic antibiotics combinations targeting the bacterial ribosomes.
Please enquire regarding licensing or codevelopment partnerships quoting reference no. 1552.
Last Updated May 2015